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Spironolactone and potassium canrenoate are di-
uretics that are used widely for management of 
cirrhotic ascites. The administration of spironolac-
tone frequently leads to feminization, which has 
been noted less frequently with the use of potassium 
canrenoate, a salt of the active metabolite of spi-
ronolactone. The use of these two drugs has been 
associated with decreases in serum testosterone lev-
els and spironolactone with a reduction in androgen 
receptor (AR) activity. This decrease in AR has been 
cited as the cause of the anti androgen effect of these 
drugs. We therefore assessed the effect of both drugs 
on levels of androgen and estrogen receptors (ER) in 
the liver, a tissue that is responsive to sex steroids. 
Three groups of male rats (n = 12 rats each) were 
studied. Group 1 (control) received vehicle only; 
group 2 received spironolactone (5 mg/day); group 3 
received potassium canrenoate (5 mg/day). After 21 
days of treatment, the animals of all groups were 
killed and liver tissue was assayed for nuclear and 
cytosolic AR and ER, and for male specific estrogen 
binder (MEB), an androgen-responsive protein. Both 
drugs drastically decreased the nuclear AR content, 
as compared with the control group, but only spi-
ronolactone decreased cytosolic AR. When the total 
hepatic content of AR is considered, a highly signif-
icant decrease is observed only in rats treated with 
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spironolactone. This reduction in hepatic AR con-
tent suggested loss of androgen responsiveness of 
liver. We confirmed this by assessing levels of MEB , 
and found that livers from group 2 animals had no 
detectable MEB activity, whereas livers from both 
group 1 and 3 had normal MEB activity. No changes 
were observed in nuclear ER and cytosolic ER of 
group 3 as compared with group 1. Nuclear estrogen 
receptor decreased and cytosolic ER increased in 
group 2, but with no change in total ER content. 
These results indicate that (a) only spironolactone 
appears to act as an antiandrogen in liver, resulting 
in a decrease in both AR and male specific estrogen 
binder content, and (b) neither drug results in ele-
vated hepatic ER content, although spironolactone-
treated animals show an altered subcellular local-
ization. 
It has been demonstrated by several lines of evidence 
that liver is an organ responsive to sex hormones. 
Estrogen receptors (ER) and androgen receptors (AR) 
have been characterized in the cytosol and nuclei of 
liver of several animal species and in humans (1-13). 
The level of these receptors in the liver is dependent 
to a great extent on the plasma level of the specific 
hormone, but growth hormone appears to be critical 
in the regulation of sexual dimorphism of liver 
function as well. The resultant masculine or femi-
nine pattern of steroid receptors and steroid metab-
olizing enzymes has an important role in maintain-
ing the sex hormone homeostasis particular to that 
sex (11,12,14). 
Abbreviations used in this paper: AR, androgen receptor; ER, 
estrogen receptor; [3H]R1881, 17 a-methyl-[3Hlmethyltrienolone; 
MEB, male specific estrogen binder. 
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Spironolactone and the potassium salt of its active 
metabolite potassium canrenoate are two drugs used 
frequently in chronic hepatic disease and to varying 
extents have been found to lead to feminization, 
impotence, and decrease of libido in male patients 
(15-19). These side effects appear to be less frequent 
with use of potassium canrenoate than with spirono-
lactone (20,21). Different explanations have been 
offered for the hormonal changes induced by these 
drugs, and spironolactone in particular. These in-
clude reduction in testosterone synthesis (22,23)' 
increase in testosterone clearance (23), reduction of 
5a-reductase activity (24), and interference with AR 
activity (25). To date, no report has defined the 
effects of these drugs on the sex hormone receptor 
state of the liver. Considering the critical role of the 
liver in sex hormone metabolism, a study of this 
aspect could add new information concerning the 
mechanisms of feminization by these two drugs. We 
report here the effect of spironolactone and potas-
sium canrenoate treatment on the sex hormone re-
ceptor and androgen responsive protein status of the 
liver and the effects of these treatments on serum 
estrogen and testosterone levels. 
Materials and Methods 
Animals 
Three groups of adult male Sprague-Dawley rats 
(240 g) were studied. Animals in the control group (group 
1) were injected intraperitoneally with 0.5 ml of a solution 
of physiologic saline with Tween 80 (0.1% vol/vol). The 
rats in the other groups received 5 mg of spironolactone 
(group 2) or 5 mg of potassium canrenoate (group 3) 
dissolved in the same vehicle. All animals were injected 
daily for 21 days, and killed by decapitation after that 
time. 
Materials 
Spironolactone and potassium canrenoate were 
from SPA, Milano, Italy. Radioactive (2, 4, 6, 7. 16, 
17)-[3Hlestradiol WH1Ez)' 131 Ci/mmol; 17 a-methyl-
[3Hlmethyltrienolone ([3H1R1881). 79 Ci/mmol; and non-
radioactive R1881 were obtained from New England Nu-
clear. Boston, Mass. The radiolabeled steroids used in 
these studies were assayed periodically for purity by 
thin-layer chromatography on silica gel G in ethyl 
acetatelhexane/ethanol (85: 10: 5), and were used only if 
purity was >95%. The sources of other materials have 
been described elsewhere (26.27). 
Androgen Receptor Studies 
Cytosolic and nuclear fractions were prepared as 
noted in Reference 28. Cytosolic androgen binding was 
quantitated using the multiple-point [3H1R1881 (0.2-5.0 
nM [3H]R1881) binding assay described in detail previ-
ously (28,29). Characterization of the [3H1R1881 binding 
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activity as a cytosolic AR has been reported elsewhere 
(10,12,28). No metabolism of [3H1R1881 could be detected 
under our incubation conditions. Because of the large 
number of animals used in these experiments, the one-
point assay described previously (26,28,29) was used to 
quantitate nuclear AR rather than multiple-point analysis. 
The validity of this assay has been described previously; 
values obtained from the one-point assay agree well with 
those from multiple-point assay (29). Evidence that 
[3H1R1881 binding represents nuclear AR has been de-
scribed elsewhere (10,28). 
Assay of Androgen-Responsive Male 
Estrogen Binding Protein 
Assays for the determination of cytosolic content of 
a male specific estrogen binder (MEB) has been described 
previously (27). Briefly, cytosol is preincubated for 1 hat 
O°C with 500 nM diethylstilbestrol to block ERs. The 
cytosol is then incubated with 5 nM [3H]Ez, [3H]estradiol 
in the absence and presence of several concentrations (5 
nM-5 .uM) of unlabeled estradiol for 2 h at DoC. Bound and 
free steroid are separated by centrifuge-assisted BioGel P-6 
chromatography (27). This assay is quantitative for MEB 
and is linear over a broad range of protein concentrations. 
A typical saturation curve analysis is illustrated in Figure 
1 of Reference 27. 
Estrogen Binding Studies 
The protamine sulfate precipitate method used to 
assay cytosolic ER and the exchange assay used to measure 
nuclear ER were identical to those described previously 
(26,28,29). 
Other Methods 
Protein concentrations were determined by the 
method of Bradford (30). Deoxyribonucleic acid concen-
trations of homogenates and nuclear preparations were 
determined by the method of Burton (31). Corrections for 
receptor content expressed on the basis of wet weight of 
liver, and assessment of purity of subcellular fractions 
have been described previously (29). Serum testosterone, 
estradiol, and other hormones were determined by specific 
radioimmunoassays as described previously (32). Equilib-
rium dissociation constants and the concentration of cyto-
solic binding sites for receptor and MEB activity were 
calculated by the method of Scatchard (33). Unweighted 
linear regression analysis of Scatchard plots was per-
formed on a TI55-III calculator (Texas-III Instruments, Inc., 
Dallas, Tex.). Statistical analyses were performed using the 
Student's t-test program available on the Hewlett-Packard 
9815S (Hewlett-Packard, Co., Palo Alto, Calif.). All results 
are expressed as mean ± SD. 
Results 
Table 1 shows the levels of several gonadal 
and pituitary hormones in the blood of control rats 
and those treated with spironolactone and potas-
sium canrenoate. In those animals treated with spi-
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Table 1. Plasma Hormone Levels in Control Rats and in Rats Treated With Spironolactone and Potassium Canrenoate 
Potassium 
Control group Spironolac- canrenoate 
1 tone group 2 po group 3 po 
Testosterone (ng/ml) 1.8 ± 0.32 0.80 ± 0.24 <0.05 1.5 ± 0.30 NS 
Estradiol (pg/ml) 9.8 ± 1.2 7.9 ± 2.1 NS 9.6 ± 1.1 NS 
Estriol (ng/ml) 1.26 ± 0.48 1.68 ± 0.69 NS 1.18 ± 0.39 NS 
Progesterone (ng/ml) 3.93 ± 0.27 3.21 ± 0.53 NS 2.71 ± 0.38 <0.05 
DHEAS (ng/ml) 99.60 ± 22.3 105.0 ± 22.4 NS 38.6 ± 15.3 <0.05 
FSH (mUlml) 1.75 ± 0.34 2.46 ± 0.37 NS 1.19 ± 0.25 NS 
PRL (mUlml) 7.02 ± 0.77 6.8 ± 0.3 NS 5.95 ± 0.60 NS 
LH (mUlml) 6.52 ± 1.02 4.76 ± 0.8 NS 4.93 ± 0.93 NS 
DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; NS, not significant; PRL, 
prolactin. Group 1 was treated with vehicle. The other groups received spironolactone (group 2) and potassium canrenoate (group 3) at 
the dosage of 5 mg/day for 21 days. Values are expressed as mean ± SD. "Values that differ from control values. 
ronolactone, there is a significant decrease in testos-
terone levels; all other hormone levels in this group 
are comparable to those of the control animals. In 
those treated with potassium canrenoate, no change 
was observed in either testosterone or estradiol lev-
els, although significant reductions in progesterone 
and dehydroepiandrosterone sulfate were found. 
Figure 1 reports the activity and subcellular dis-
tribution of AR in the livers of these animals. Cyto-
solic AR levels (Figure lC) are significantly higher in 
those rats treated with potassium canrenoate than in 
either the control animals or the animals treated 
with spironolactone. There were no variations in the 
affinity of the cytosolic AR for its ligand in any 
groups studied. Specifically, the equilibrium disso-
ciation constant values for cytosolic AR were 0.26 ± 
0.06, 0.25 ± 0.08, and 0.31 ± 0.04 nM for groups 1, 
2, and 3, respectively. The activity of nuclear AR, 
however, presents a markedly different picture, and 
is significantly decreased in the animals treated with 
either spironolactone or potassium canrenoate (Fig-
ure IB). As a result of these variations, the total AR 
content of the liver (Figure lA) changed significantly 
only in those animals treated with spironolactone 
(50% decrease from normal levels). Interestingly, the 
activity of total AR in the spironolactone-treated 
animals shows a decrease proportional to that of 
plasma testosterone (Figure ID). 
Because total hepatic AR activity and plasma 
testosterone values were reduced in the spironolac-
tone-treated animals, the activity of a hepatic andro-
gen responsive protein, a MEB, was also assessed. 
Figure 2 shows that the activity of this protein is 
undetectable in the livers of those animals treated 
with spironolactone; this loss of MEB activity is 
comparable to that seen in rats castrated at least 15 
days before death (10,12). However, the level of MEB 
in the rats treated with potassium canrenoate is 
actually higher than that observed in the control rats. 
The loss of expression of MEB after spironolactone 
treatment suggests that this drug may be interfering 
with androgen action. To determine whether either 
of these drugs might interfere by competing for 
androgen binding to its receptor, we tested whether 
they were capable of competing for AR binding in an 
in vitro assay. As shown in Figure 3, spironolactone, 
at a 100-fold and 1000-fold excess, is partially effec-
tive as a competitor for [3H]R1881 binding in rat liver 
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Figure 1. Variation in specific [3H]R1881 in rat liver of male rats 
treated with spironolactone (SPIRO) or potassium 
canrenoate (K-CAN). Specific [3H]R1881 binding was 
quantitated as described in Methods and is expressed 
as femtomoles per gram liver. Total hepatic receptor 
content is shown in A, nuclear receptor in B, and 
cytosolic receptor in C. Serum testosterone levels are 
shown in D. All groups consisted of at least 5 animals; 
the values are expressed as mean ± SD. "Different from 
control, p < 0.05. 
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cytosol. The strong androgens R1881 and dihydro-
testosterone, however, are much more effective com-
petitors than is spironolactone. In contrast, potas-
sium canrenoate is incapable of competing for 
[3H]R1881 binding at any concentration tested. 
When these substances were tested at 100-fold ex-
cess using nuclear preparations, the competition 
observed was virtually identical to that for the cyto-
solic AR except that, in nuclei, dihydrotestosterone 
was equivalent to R1881 in effectiveness. 
In other studies, the activity and subcellular dis-
tribution of hepatic estrogen receptors in the three 
groups of animals were examined. The activity of 
cytosolic ER was virtually unchanged among the 
three groups (group 1,445 ± 61; group 2, 553 ± 150; 
group 3,441 ± 94 fmol/g liver), nor did the affinity of 
cytosolic ER for estradiol vary among the groups of 
animals (equilibrium dissociation constant values of 
0.26 ± 0.07, 0.45 ± 0.12, and 0.36 ± 0.08 nM for 
groups 1, 2, and 3, respectively). The activity of 
nuclear ER was decreased significantly (p < 0.05) 
only in that group of animals treated with spirono-
lactone (178 ± 44, 67.2 ± 16, and 209 ± 44 fmol/g 
liver for groups 1, 2, and 3, respectively). However, 
the total hepatic ER content does not vary in the 
three groups of animals studied (group 1, 673 ± 113; 
group 2, 600 ± 88; and group 3, 650 ± 90 fmol/g 
liver). This latter finding is consistent with the 
similar plasma estradiol values in these three groups 
of animals (Table 1). 
Discussion 
Liver is a sex steroid-responsive organ in both 
male and female animals. Many biochemical events, 
particularly those regarding drug and sex hormone 
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Figure 2. Activity of an androgen responsive protein in liver of 
male rats treated with spironolactone (SPIRO) or potas-
sium canrenoate (K-CAN). Cytosolic MEB was mea-
sured by its [3H]estradiol ([3H]E2) binding activity as 
described in Methods. All groups consisted of at least 5 
animals; the values are expressed as mean ± SO. 
*Different from control. p < 0.05. 
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Figure 3. Specificity of binding to cytosolic proteins in male rat 
liver cytosoL Two hundred microliters of male rat liver 
cytosol were incubated with 1.5 nM [3H]R1881 in the 
absence (control, 100%) and presence of 1-, 10-, 100-. 
and 1000-fold excess of potentially competing drugs or 
hormones. 0, control = 100%; e-e, [3H]R1881; A-A, 5 
a-dihydrotestosterone; 6-6, spironolactone (SPIRO); 
0-0, potassium canrenoate (K-CAN). 
metabolism, are influenced by the sex of the animal. 
This sexual dimorphism of liver function has been 
observed in both animals and humans (reviewed in 
Reference 11). In male rats, androgen is the major 
determinant of the masculine pattern of liver func-
tion. Androgen stimulates the expression of both 
androgen receptor and certain enzymes and proteins 
such as MEB (10,12). This masculine pattern can be 
feminized by certain changes in serum hormone 
levels occurring after castration (10,12)' chronic al-
cohol ingestion (5), estrogen treatment (34), and 
portal vein ligation (35), and during liver regenera-
tion (26,29). 
It is known from the clinical literature that spi-
ronolactone has feminizing action. There have been 
many reports addressing the mechanism of this 
action. Menard et al. (22) demonstrated, in several 
species, that spironolactone treatment decreases the 
microsomal cytochrome P 450 content of the testes 
and reduces the activity of 17-hydroxylase, an en-
zyme necessary for testosterone synthesis. In women 
treated with spironolactone to reduce hirsutism, this 
drug has been shown to increase testosterone clear-
ance (23) and decrease genital skin fibroblast steroid 
50' reductase (24). Loriaux et al. (36) showed, using 
an in vitro assay, that spironolactone inhibits the 
binding of dihydrotestosterone to the AR. Chopra et 
al. (37) reported that in general such feminization is 
a result of an alteration of testosterone-estrogen 
balance. 
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Our results present further observations on the 
action of spironolactone. Administration of this drug 
resulted in a significant decrease in plasma of testos-
terone levels and hepatic AR and the complete loss 
of activity of the androgen responsive hepatic pro-
tein MEB. As we have reported previously (4,12,27), 
MEB is a cytosolic protein that has a moderate 
affinity for estradiol, high binding capacity, and 
specificity for steroidal estrogen. Its function in the 
cytosol of male rats is unknown, but may be that of 
an intracellular estrogen scavenger (4,27). The com-
plete disappearance of MEB in rats treated with 
spironolactone is significant because, first, its loss 
represents interruption of hepatic androgen re-
sponse, and second, its absence might lead to an 
increased intracellular estrogen concentration. 
The loss of MEB only in the spironolactone-treated 
animals is interesting, as both drug groups demon-
strated reduced nuclear AR levels. However, only 
the spironolactone group demonstrated reduced se-
rum testosterone. It is possible that the nuclear AR 
has either a higher affinity in vivo for spironolactone 
than for testosterone, or the spironolactone is avail-
able at much higher concentrations than testosterone 
to interact with the nuclear AR. Because we did not 
measure serum levels of either drug, it is not possible 
to differentiate between these possibilities. It is clear, 
however, that the presence of spironolactone inhib-
its the expression of MEB; this reduced expression is 
likely to result from an unproductive interaction of 
the drug with AR. 
In spite of the loss of MEB activity, our results 
display no action of spironolactone either on plasma 
estradiol or estriol content, or on the total ER activity 
in liver. It is possible that our treatment period was 
too short to produce a feminization of (Le., an 
increase in) these activities. It is more likely, how-
ever, that in liver disease patients, feminization 
occurs because spironolactone treatment interferes 
in maintaining the androgenic influence necessary to 
sustain a masculine pattern of liver function. Such 
interference, coupled with an already compromised 
ability to excrete estrogens, may permit full femini-
zation of liver and other peripheral tissues, such as 
the breast. However, our experimental animals dis-
play no liver disease; thus, treatment of normal male 
animals with spironolactone may not result in the 
pronounced feminization that has been noted in 
some patients with liver disease. 
Our results in animals treated with potassium 
canrenoate, the major active metabolite of spirono-
lactone, confirmed the clinical data indicating that 
this drug has less antiandrogenic effect than spirono-
lactone. Use of potassium canrenoate has been 
shown to reverse the gynecomastia produced during 
treatment with spironolactone (20,38), and shows a 
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much lower incidence of the feminizing side effects 
of cirrhotic patients (38). It has been demonstrated, 
in castrated animals, that potassium canrenoate does 
not inhibit cytochrome P 450, as does spironolactone, 
and produces significantly less androgenic antago-
nism (39). Thus, our results in animals chronically 
treated with potassium canrenoate confirm the clin-
ical findings. In fact, no decrease of plasma testos-
terone, total hepatic AR, or MEB, and no inhibition 
of androgen binding to its receptor were found to 
occur in the liver of these animals. Although no 
decrease was observed in these androgen-related 
functions, it was noted that potassium canrenoate 
also resulted in a decrease in nuclear AR. Perhaps 
the normal serum testosterone in these animals was 
sufficient to maintain an adequate androgenic re-
sponse in spite of the reduced nuclear AR levels. 
Another possibility is that this drug somehow pro-
motes release of the nuclear AR into the cytosolic 
fraction. The latter possibility is consistent with our 
findings of increased cytosolic AR in these animals. 
In conclusion, the data reported in this paper 
demonstrate that spironolactone treatment of male 
rats decreased plasma testosterone and exhibited a 
powerful anti androgenic effect, as documented by 
the low levels of hepatic AR and disappearance of an 
androgen responsive hepatic protein, MEB. We also 
demonstrated that potassium canrenoate did not 
show any of the antiandrogenic actions of spirono-
lactone in the liver, suggesting that the clinical 
improvement reported in patients treated with po-
tassium canrenoate as compared with spironolac-
tone is the result of this biochemical difference. 
Also, our results indicate that in animals with no 
underlying liver disease, there is no increase in 
plasma estrogen levels or total hepatic ER content. 
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